Quality of life in chronic lymphocytic leukemia: A neglected issue

References

• Schilsky R L. End point in clinical trials and the drug approval process. Clinical Cancer Research 2002; 8: 935–938
   PubMed Web of Science ®Google Scholar
• Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, et al. Guidlines on the diagnosis and management of chronic lymphocytic leukemia. British Journal of Haematology 2004; 125: 294–317
   PubMed Web of Science ®Google Scholar
• Muldoon M F, Barger S D, Flory J D, Nanuck S B. What are quality of life measurements measuring?. British Medical Journal 1998; 316: 542–545
   PubMed Web of Science ®Google Scholar
• Mauro F R, Foa R. Young patients with chronic lymphocytic leukemia. Chronic lymphocytic leukaemia, G B Faguet. Humana Press, Totowa, NJ 2004; 401–413
   Google Scholar
• Byrd J C, Stilgenbauer S, Flinn I W. Chronic lymphocytic leukemia. Hematology 2004; 163–183
   PubMedGoogle Scholar
• Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology 1998; 11A: 369–377
   Google Scholar
• Uggla C, Aguillar-Santelises M, Rosen A, Mellstedt H, Jondel M. Spontaneous production of interleukin-1 activity by chronic lymphocytic leukemia cells. Blood 1987; 70: 1851–1857
   PubMed Web of Science ®Google Scholar
• Fayad A, Keating M J, Reuben J M, O'Brien S, Lee B N, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–263
   PubMed Web of Science ®Google Scholar
• Foa R, Massaia M, Cordone S, Tos A G, Attisano C, Guarini A, et al. Production of tumor necrosis factor alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of disease. Blood 1990; 76: 393–400
   PubMed Web of Science ®Google Scholar
• Ludwig H, Rai K, Blade J, Dammacco F, Degos L, Itri L, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoietin treatment recommendations. The Hematology Journal 2002; 3: 121–130
   Google Scholar
• Littlewood T, Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Seminars in Oncology 2002; 29: 40–44
   PubMed Web of Science ®Google Scholar
• Harrison L B, Shasha D, White C, Ramdeen B. Radiotherapy-associated anemia: the scope of the problem. The Oncologist 2000; 5: 1–7
   Google Scholar
• Rossi J F, Van Hoof A, De Boeck K, Johnson S A, Bron D, Foussard C, et al. Efficacy and safety of oral fludarabine phosphate in patients with untreated CLL. Journal of Clinical Oncology 2004; 21: 1260–1267
   Web of Science ®Google Scholar
• Cassileth B R, Lusk E J, Strouse T B, Miller D S, Brown L L, Cross P A, Tenaglia A N. Psychosocial status in chronic illness. New England Journal of Medicine 1984; 311: 506–511
   PubMed Web of Science ®Google Scholar
• Breetvel I S, van Dam F S. Underreporting by cancer patients: the case of response-shift. Society of Science Medicine 1991; 32: 981–987
   PubMed Web of Science ®Google Scholar
• Addington-Hall J, Kalra L. Who should measure quality of life. British Medical Journal 2001; 322: 1417–1420
   PubMed Web of Science ®Google Scholar
• Byrd J C, Rai K, Peterson B L, Appelbaum F R, Morrison V A, Kolitz J E, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S. Evaluating treatment strategies in chronic lymphocytic treatment strategies: use of quality-adjusted survival analysis. Journal of Clinical Epidemiology 2001; 54: 747–754
   PubMed Web of Science ®Google Scholar
• Oliva E N, D'Angelo A, Martino B, Nobile F, Dimitrov B D, Perna A. More concern about transfusion requirement when evaluating quality of life in anemic patients. Journal of Clinical Oncology 2002; 20: 3182–3183
   PubMed Web of Science ®Google Scholar
• Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Journal of Clinical Oncology 1997; 15: 1218–1234
   PubMed Web of Science ®Google Scholar
• Demetri G D, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Journal of Clinical Oncology 1998; 16: 3412–3425
   PubMed Web of Science ®Google Scholar
• Abels R. Erythropoietin for anaemia in cancer patients. European Journal of Cancer 1993; 29((Suppl 2))2–8
   Web of Science ®Google Scholar
• Sabbatini P. The relationship between anaemia and quality of life in cancer patients. The Oncologist 2000; 5((Suppl 2))19–23
   Google Scholar
• Littlewood T J, Bajetta E, Nortier J WR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2001; 19: 2865–2874
   PubMed Web of Science ®Google Scholar
• Gabrilove J L, Cleeland C S, Livingston R B, Sarokhan B, Winer E, Einhorn L H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in haemoglobin and quality of life are similar to three-times weekly dosing. Journal of Clinical Oncology 2001; 19: 2875–2882
   PubMed Web of Science ®Google Scholar
• Cleeland C S, Demetri G D, Glaspy J, Cella D F, Russell K P, Cremieux P Y, Itri L M. Identifying haemoglobin level for optimal quality of life: results of an incremental analysis. Proceedings of the American Society of Clinical Oncology 1999; 18: 547
   Google Scholar
• Rose E, Rai K, Revicki D, Brown R, Reblando J. Clinical and health status assessment in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994; 84((Suppl))526a
   PubMedGoogle Scholar
• Pangalis G A, Siakantasis M P, Angelopoulou M K, Vassilakopoulos T P, Dimopoulou M N, Kyrtsonis M C, et al. Downstaging Rai III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 2002; 87: 570–575
   Web of Science ®Google Scholar
• Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leukemia and Lymphoma 1994; 13: 203–214
   PubMed Web of Science ®Google Scholar
• Bodey G P, Kantoyannis D, Keating M J. Infections in patients with chronic lymphocytic leukemia. Chronic lymphocytic leukaemia, G B Faguet. Humana Press, Totowa, NJ 2004; 343–359
   Google Scholar
• Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoria L, , Cooperative Group for the study of Immunoglobulin in Chronic Lymphocytic Leukemia, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. New England Journal of Medicine 1988; 319: 902–907
   PubMed Web of Science ®Google Scholar
• Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81: 121–126
   PubMed Web of Science ®Google Scholar
• Weeks J C, Tierney M R, Weinstein M C. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. New England Journal of Medicine 1991; 325: 81–86
   PubMed Web of Science ®Google Scholar
• Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia. Haematologia 2001; 86: 8–12
   Google Scholar
• Charlson M E, Pompei P, Ales K, Mackenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies; development and validation. Journal of Chronic Diseases 1987; 40: 373–383
   PubMedGoogle Scholar
• Miller M D, Paradis C F, Houck P R, Mazumdar S, Stack J A, Rifai A H, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Research 1992; 41: 237–248
   PubMed Web of Science ®Google Scholar
• Folstein M F, Folstein S E, McHugh P R. ‘Mini Mental State’: a practical method for grading the cognitive status of patiens for the clinician. Journal of Psychiatric Research 1975; 12: 189–198
   PubMed Web of Science ®Google Scholar
• Hudson J. Nutrition, cancer and aging. Comprehensive geriatric oncology 2nd ed, L Balducci, G H Lynon, W B Ershler. Harwood Academic Publishers, Amsterdamthe Netherlands 1998; 301–306
   Google Scholar
• Hutner Wirograd C, Gerety M H, Chung M. Screening for frailty: criteria and predictors of outcomes. Journal of the American Geriatric Society 1991; 39: 778–784
   PubMed Web of Science ®Google Scholar
• Cella D F. Measuring quality of life in palliative care. Seminars in Oncology 1995; 22((Suppl 3))73–81
   PubMed Web of Science ®Google Scholar
• Cella D F, Tulsky D S, Gray G, Seration B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993; 11: 570–579
   PubMed Web of Science ®Google Scholar
• Aaronson N K, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N J, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. European Organization for Research and Treatment of Cancer. Journal of National Cancer Institute 1993; 85: 365–376
   PubMed Web of Science ®Google Scholar
• Holzner B, Kemmler G, Kopp M, Nguyen-Van-Tam D, Sperner-Unterweger B, Greil R, et al. Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over one year. European Journal of Haematology 2004; 72: 381–389
   PubMed Web of Science ®Google Scholar
• Molica S, Mauro F R, Callea V, Gentile M, Giannarelli D, Lopez M, et al. A gender based score system predicts clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leukemia and Lymphoma 2005; 46: 553–560
   PubMed Web of Science ®Google Scholar